Article

CTMA Expands to Rheumatology

CTMA has announced that it is expanding its CT-SCOUT™ technology offering into a second therapeutic area–rheumatology. CT-SCOUT™, the company’s multi-device platform that allows health care professionals (HCP) to identify trial candidates, will now be available for sites, sponsors and contract research organizations (CROs) in three rheumatological indications: Rheumatoid Arthritis, Ankylosing Spondylarthritis and Psoriatic Rheumatism.

Read more about the announcement here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.